Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET

The Massachusetts General Hospital Radiochemistry Program, in collaboration with Pfizer, has developed unique 11 C and 18 F-labeling strategies to synthesize isotopologs of lorlatinib (PF-06463922) which is undergoing phase III clinical trial investigations for treatment of non-small-cell lung cance...

Full description

Bibliographic Details
Main Authors:	T. Lee Collier PhD, Kevin P. Maresca PhD, Marc D. Normandin PhD, Paul Richardson PhD, Timothy J. McCarthy PhD, Steven H. Liang PhD, Rikki N. Waterhouse PhD, Neil Vasdev PhD
Format:	Article
Language:	English
Published:	SAGE Publishing 2017-10-01
Series:	Molecular Imaging
Online Access:	https://doi.org/10.1177/1536012117736669

Similar Items

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
by: Hidetoshi Hayashi, MD, PhD, et al.
Published: (2023-04-01)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
by: Parvin Begum, PhD, et al.
Published: (2022-09-01)

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance
by: Malinda Itchins, BMedSci, M.B.B.S., FRACP, PhD, et al.
Published: (2024-09-01)

Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study
by: Shunsuke Teraoka, MD, et al.
Published: (2024-03-01)

Preclinical PET Neuroimaging of [C]Bexarotene
by: Benjamin H. Rotstein PhD, et al.
Published: (2016-08-01)

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
by: Qing Zhou, MD, PhD, et al.
Published: (2023-05-01)

Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
by: Vidya Narayanaswami PhD, et al.
Published: (2018-09-01)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
by: Yasushi Goto, MD, PhD, et al.
Published: (2023-05-01)

Improving PET Imaging Acquisition and Analysis With Machine Learning: A Narrative Review With Focus on Alzheimer's Disease and Oncology
by: Ian R. Duffy PhD, et al.
Published: (2019-08-01)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
by: Rohit Thummalapalli, MD, et al.
Published: (2023-08-01)

Advanced multiparametric MRI and FDG-PET/CT in multinodular and vacuolating neuronal tumor: A pathologically confirmed case
by: Seiya Kishi, MD, et al.
Published: (2023-09-01)

Fluorodeoxyglucose positron emission tomography (FDG/PET) shows the effect of carbon-ion radiotherapy (CIRT); with pathologic confirmation
by: Jun Aoki, MD, et al.
Published: (2023-05-01)

Central nervous system involvement of systemic ALK-positive histiocytosis with KIF5B-ALK fusion
by: Yuzuna Aoki, MD, et al.
Published: (2022-10-01)

Histopathological Confirmation of Axonal Sprouting in Regenerative Peripheral Nerve Interface
by: Song Ho Chang, MD, PhD, et al.
Published: (2024-06-01)

First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
by: Umair Majeed, MD, et al.
Published: (2023-07-01)

Multiscale Mask R-CNN–Based Lung Tumor Detection Using PET Imaging
by: Rui Zhang PhD, et al.
Published: (2019-07-01)

Comparison of New Tau PET-Tracer Candidates With [F]T808 and [F]T807
by: Lieven Declercq Pharmacist, et al.
Published: (2016-01-01)

Detecting Demyelination by PET: The Lesion as Imaging Target
by: Pedro Brugarolas PhD, et al.
Published: (2018-07-01)

The Search for a Subtype-Selective PET Imaging Agent for the GABA Receptor Complex: Evaluation of the Radiotracer [C]ADO in Nonhuman Primates
by: Shu-fei Lin PhD, et al.
Published: (2017-09-01)

Quantification of Cerenkov Luminescence Imaging (CLI) Comparable With 3-D PET Standard Measurements
by: Frezghi Habte PhD, et al.
Published: (2018-07-01)

Application of Immuno-PET in Antibody–Drug Conjugate Development
by: Kendra S. Carmon PhD, et al.
Published: (2018-10-01)

PET/SPECT Molecular Probes for the Diagnosis and Staging of Nonalcoholic Fatty Liver Disease
by: Tuo Shao PhD, et al.
Published: (2019-09-01)

Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [F]DPA-714 PET Imaging
by: Clément Thomas MD, et al.
Published: (2016-04-01)

Radionuclide Imaging for Neuroscience: Current Opinion and Future Directions
by: Antony D. Gee PhD, et al.
Published: (2020-09-01)

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
by: Benjamin J. Solomon, M.B.B.S., PhD, et al.
Published: (2024-07-01)

Music Therapy and Music Intervention for NSCLC Patients Undergoing PET with Fear of Cancer Recurrence
by: Yi-jie Du PhD, et al.
Published: (2024-08-01)

Effect of the TAAR1 Partial Agonist Ralmitaront on Presynaptic Dopamine Synthesis Capacity Measured Using [F]DOPA PET in Naïve and Cocaine-Treated Mice
by: David R. Bonsall PhD, et al.
Published: (2024-12-01)

Evaluation of a BGO-Based PET System for Single-Cell Tracking Performance by Simulation and Phantom Studies
by: Yu Ouyang PhD, et al.
Published: (2016-05-01)

Quantification of Multi-Organ 11β-Hydroxysteroid Dehydrogenase Type 1 Enzyme Levels in a Zucker Fatty Rat Model: A PET Imaging Study
by: Jason Bini PhD, et al.
Published: (2024-12-01)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
by: Ming-Hung Huang, PhD, et al.
Published: (2022-11-01)

PET Study of Sphingosine-1-Phosphate Receptor 1 Expression in Response to Vascular Inflammation in a Rat Model of Carotid Injury
by: Hui Liu PhD, MD, et al.
Published: (2017-01-01)

Detecting Cardiac Involvement in the Idiopathic Inflammatory Myopathies Using Cardiovascular Magnetic Resonance and 18F-FDG-PET/CT
by: Gautam Sen, et al.
Published: (2024-01-01)

Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18
by: Dae-Ho Choi, MD, et al.
Published: (2024-12-01)

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma
by: Karl Grenier, MD, PhD, et al.
Published: (2023-07-01)

Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
by: Wojciech G. Lesniak PhD, et al.
Published: (2019-06-01)

Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications
by: Hamideh Zarrinmayeh PhD, et al.
Published: (2020-06-01)

Longitudinal Evaluation of Myocardial Fatty Acid and Glucose Metabolism in Fasted and Nonfasted Spontaneously Hypertensive Rats Using MicroPET/CT
by: Jennifer S. Huber PhD, et al.
Published: (2017-08-01)

Immune system dysregulation preceding a case of laboratory-confirmed zoster/dermatitis on board the International Space Station
by: Satish K. Mehta, PhD, et al.
Published: (2024-05-01)

Preoperative factors affecting the two-year postoperative patient-reported outcome in single-level lumbar grade I degenerative spondylolisthesis
by: Tsukasa Kanchiku, PhD, et al.
Published: (2023-12-01)

Magnetic Resonance Imaging of Mammalian Cells Individually Expressing Membrane-Associated Magnetosome Proteins I, L, B, and E
by: Qin Sun PhD, et al.
Published: (2024-10-01)